Cardio Diagnostics Holdings, Inc. (CDIO) compared with its closest peers (ADVB, ACON, SERA, QCLS, VNRX). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Advanced Biomed Inc. Common Stock, Aclarion, Sera Prognostics, OneMedNet, iSpecimen and 20/20 Biolabs, Inc. Common Stock share Cardio Diagnostics's business model, clinical labs / cro services.
| Company | Market Cap | P/E |
|---|---|---|
| Advanced Biomed Inc. Common Stock (ADVB) | $13.27M | 3.2 |
| Aclarion, Inc. (ACON) | $5.96M | -0.3 |
| Sera Prognostics, Inc. (SERA) | $101.96M | -4.3 |
| Q/C Technologies, Inc. (QCLS) | $15.68M | -0.5 |
| VolitionRx Limited (VNRX) | $3.15M | — |
| Insight Molecular Diagnostics Inc. (IMDX) | $131.55M | -4.5 |
| Biomerica, Inc. (BMRA) | $10.05M | -1.4 |
| OneMedNet Corporation (ONMD) | — | — |
| iSpecimen Inc. (ISPC) | $3.78M | -0.1 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $8.05M | — |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
CDIO overview · CDIO earnings · CDIO financials · CDIO KPIs · CDIO documents · CDIO ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.